1. Home
  2. HCAI vs AVIR Comparison

HCAI vs AVIR Comparison

Compare HCAI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCAI
  • AVIR
  • Stock Information
  • Founded
  • HCAI 2004
  • AVIR 2012
  • Country
  • HCAI China
  • AVIR United States
  • Employees
  • HCAI N/A
  • AVIR N/A
  • Industry
  • HCAI Miscellaneous manufacturing industries
  • AVIR Medicinal Chemicals and Botanical Products
  • Sector
  • HCAI Consumer Discretionary
  • AVIR Health Care
  • Exchange
  • HCAI Nasdaq
  • AVIR Nasdaq
  • Market Cap
  • HCAI 272.6M
  • AVIR 273.7M
  • IPO Year
  • HCAI 2025
  • AVIR 2020
  • Fundamental
  • Price
  • HCAI $7.61
  • AVIR $2.76
  • Analyst Decision
  • HCAI
  • AVIR Hold
  • Analyst Count
  • HCAI 0
  • AVIR 1
  • Target Price
  • HCAI N/A
  • AVIR $6.00
  • AVG Volume (30 Days)
  • HCAI 51.3K
  • AVIR 494.6K
  • Earning Date
  • HCAI 01-01-0001
  • AVIR 05-13-2025
  • Dividend Yield
  • HCAI N/A
  • AVIR N/A
  • EPS Growth
  • HCAI N/A
  • AVIR N/A
  • EPS
  • HCAI 0.11
  • AVIR N/A
  • Revenue
  • HCAI $53,677,586.00
  • AVIR N/A
  • Revenue This Year
  • HCAI N/A
  • AVIR N/A
  • Revenue Next Year
  • HCAI N/A
  • AVIR N/A
  • P/E Ratio
  • HCAI $75.52
  • AVIR N/A
  • Revenue Growth
  • HCAI 534.84
  • AVIR N/A
  • 52 Week Low
  • HCAI $3.70
  • AVIR $2.60
  • 52 Week High
  • HCAI $10.97
  • AVIR $4.15
  • Technical
  • Relative Strength Index (RSI)
  • HCAI N/A
  • AVIR 41.20
  • Support Level
  • HCAI N/A
  • AVIR $2.83
  • Resistance Level
  • HCAI N/A
  • AVIR $3.08
  • Average True Range (ATR)
  • HCAI 0.00
  • AVIR 0.13
  • MACD
  • HCAI 0.00
  • AVIR -0.01
  • Stochastic Oscillator
  • HCAI 0.00
  • AVIR 23.81

About HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: